PDGFRB and dedifferentiated liposarcoma: Responses of DDLS patients to pazopanib (which inhibits PDGFR, c-KIT, FGFR, and VEGFR) were better than those in myxoid liposarcoma, suggesting that the contribution of PDGFR signaling to DDLS progression is clinically relevant44.